Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
The current Neurocrine(NBIX) stock price is $154.99, with a market capitalization of 15.44B. The stock trades at a price-to-earnings (P/E) ratio of 37.14.
On 2025-12-08, Neurocrine(NBIX) stock traded between a low of $154.74 and a high of $160.18. Shares are currently priced at $154.99, which is +0.2% above the low and -3.2% below the high.
The Neurocrine(NBIX)'s current trading volume is 1.42M, compared to an average daily volume of 891.24K.
During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.
During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.
NBIX News
Neurocrine Biosciences (NBIX) just shared a key clinical update, revealing that its investigational depression drug NBI-1070770 missed the primary efficacy endp...
TD Cowen raised the firm’s price target on Neurocrine (NBIX) to $200 from $175 and keeps a Buy rating on the shares. The firm believes there is much growth left...
On November 20, 2025, Neurocrine Biosciences announced the publication of a comprehensive peer-reviewed narrative review consolidating over a decade of clinical...